Join the 'Restasis' group to help and get support from people like you.
Posted 28 Jan 2016 by Drugs.com
WEDNESDAY, Jan. 27, 2016 – A newer drug used for preventing organ rejection might improve the long-term outlook for kidney transplant recipients, a new study finds. Over seven years, patients given the drug belatacept (brand name: Nulojix) were 43 percent less likely to die or see their donor kidney fail compared to patients given an older drug called cyclosporine. Experts said the findings should encourage more doctors and patients to choose belatacept over standard anti-rejection medications. "This is a potentially transformational drug," said study lead researcher Dr. Flavio Vincenti, a transplant specialist at the University of California, San Francisco. The study – funded by the drug's maker, Bristol-Myers Squibb – was published in the Jan. 28 issue of the New England Journal of Medicine. Belatacept was first approved by the U.S. Food and Drug Administration in 2011 for ... Read more
Related support groups: Renal Failure, Kidney Infections, Restasis, Chronic Kidney Disease, Cyclosporine, Organ Transplant - Rejection Prophylaxis, Peritoneal dialysis, Organ Transplant, Neoral, Organ Transplant - Rejection Reversal, Pyelonephritis, Renal Osteodystrophy, Gengraf, Graft-versus-host disease, Rejection Prophylaxis, Sandimmune, Nulojix, Hyperphosphatemia of Renal Failure, Belatacept